Critics of a purely screening-focused strategy warn that diagnostic tests are only as effective as the treatment pathways that follow them. There is a significant concern that pushing for widespread early detection without simultaneously expanding the capacity for specialized treatment will lead to a bottleneck in the healthcare system. If thousands of patients are diagnosed with early-stage conditions but cannot access timely surgery, chemotherapy, or specialized ophthalmological care, the screening process itself may create unnecessary psychological distress and administrative strain.
Skeptics also point to the risk of over-diagnosis and the potential for false positives, which can lead to unnecessary medical procedures and anxiety for patients. They argue that the focus should not just be on the act of screening, but on the quality of the entire care continuum. Without a clear plan to support patients who receive a positive diagnosis, the push for early detection could inadvertently overwhelm existing public hospitals that are already operating at full capacity.
Additionally, there is the issue of affordability and the hidden costs to the patient. Even if a screening test is free or subsidized, the subsequent diagnostic work-ups and follow-up appointments often involve travel, lost wages, and out-of-pocket expenses that many families cannot afford. Accountability-focused observers suggest that policymakers must prioritize the strengthening of secondary and tertiary care facilities before launching large-scale screening campaigns to ensure that every patient identified as 'at-risk' has a clear, funded, and accessible path to recovery.